Cabaletta Bio reports positive CABA-201 data at ACR 2024; all 8 patients drug-free responses

Cabaletta Bio, Inc.

Eight patients dosed across RESET-Myositis, -SLE, -SSc trials; all off immunosuppressants through follow-up.
Favorable safety: no ICANS (except one prior LN case); low-grade CRS in 3/8, no tocilizumab needed.
Complete B cell depletion by day 22; transitional naïve B cell repopulation as early as 8 weeks in first 2 patients.
All 4 SLE patients showed clinical responses; LN patient proteinuria improved >90%. DM patient achieved major TIS response and normal muscle strength.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.